EUVIMEDEUVIMED entdecken
Multizentrische Studie

Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses

Ziyun Shen, Yue Liu, Tieyuan Zhu, Xinsheng Zhu, Yingzhi Zheng, Jianing Qiu, Meixin Teng, Pengyu Fan, Shuyu Ji, Peng Zhang iD

European Journal of Cardio-Thoracic Surgery · 2026

DOI: 10.1093/ejcts/ezag017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2026. Verfasst von Ziyun Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Thymus Neoplasms, Keratin-19, Thymoma, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The accurate differentiation of thymic masses, particularly thymic carcinoma (TC), is imperative for guiding optimal treatment selection. This study investigated potential non-invasive biomarkers for discerning thymic malignancies and evaluated their clinical applicability.

Methods

Clinicopathological data from 1897 patients who underwent surgical resection for thymic masses across 2 institutions were retrospectively analysed. Associations between serum tumour markers and TC diagnosis were assessed using the area under the receiver operating characteristic curve (AUC). The clinical utility of the identified tumour markers was further evaluated.

Results

In the discovery cohort from Shanghai Pulmonary Hospital (SPH), cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) levels were significantly higher in the TC group compared to both the thymoma group and the non-thymic epithelial tumour (non-TET) group (median of 2.38 ng/mL vs 1.39 ng/mL or 1.28 ng/mL, both P < .001), with AUC value of 0.778 (95% CI: 0.735-0.822) compared to thymoma and 0.808 (95% CI: 0.766-0.849) compared to non-TET group. Validation in the cohort from Renmin Hospital of Wuhan University further demonstrated significant discrimination of CYFRA 21-1 for TC diagnosis (vs thymoma: AUC = 0.681 [95% CI: 0.518-0.843]; vs non-TET: AUC = 0.801 [95% CI: 0.622-0.980]). Furthermore, high CYFRA 21-1 levels were also correlated with a shorter median disease-free survival compared to the low CYFRA 21-1 group (10.0 years vs 14.9 years, P < .001) in patients with TET in the SPH cohort.

Conclusions

CYFRA 21-1 emerges as a reliable diagnostic biomarker for distinguishing TC from other thymic masses. Moreover, it holds promise for prognosis evaluation and potentially for recurrence surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymus NeoplasmsKeratin-19ThymomaBiomarkers, TumorAntigens, NeoplasmHumansMaleFemaleMiddle AgedRetrospective StudiesPrognosisAgedAdult

Stichwörter der Autor:innen

CYFRA 21-1biomarkerdiagnosisprognosisthymic carcinomathymic mass

Substanzen

Keratin-19Biomarkers, TumorAntigens, Neoplasmantigen CYFRA21.1

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
  • Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

ORCID-Profile: Peng Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shen, Z., Liu, Y., Zhu, T., Zhu, X., Zheng, Y., Qiu, J., Teng, M., Fan, P., Ji, S., & Zhang, P. (2026). Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezag017

Vancouver

Shen Z, Liu Y, Zhu T, Zhu X, Zheng Y, Qiu J, et al. Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses. European Journal of Cardio-Thoracic Surgery. 2026. doi:10.1093/ejcts/ezag017

BibTeX
@article{Shen2026,
  author = {Shen, Ziyun and Liu, Yue and Zhu, Tieyuan and Zhu, Xinsheng and Zheng, Yingzhi and Qiu, Jianing and Teng, Meixin and Fan, Pengyu and Ji, Shuyu and Zhang, Peng},
  title = {Serum Cytokeratin 19 Fragment Antigen 21-1 as a Diagnostic and Prognostic Biomarker for Thymic Carcinoma in Thymic Masses},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2026},
  doi = {10.1093/ejcts/ezag017}
}
Kostenlos starten →